RhoVac is an immunotherapy company listed on the Spotlight stock market in Sweden, with a 100%-owned subsidiary in Denmark. It is developing a peptide-based immunotherapy, RV001, which aims to train the immune system to specifically target cancer cells with metastatic potential.
More RhoVac content >Investment summary
RhoVac’s Phase IIb BRaVac trial has been fully enrolled since September 2021. The study reached Database Lock on 10 May and primary outcome in anticipated at end May or early June 2022, which is the most significant catalyst of the investment case so far. RhoVac’s lead asset is RV001 (onilcamotide), a tissue-agnostic cancer immunotherapy. It contains a fragment of the target protein RhoC, which is overexpressed in cells with metastatic potential in various cancers. The BRaVac trial investigates RV001 in prostate cancer patients with localised disease who have relapsed after treatment with curative intent. The latest interim safety review (December 2021) found no issues.
Y/E Dec |
Revenue (SEKm) |
EBITDA (SEKm) |
PBT (SEKm) |
EPS (fd) (öre) |
P/E (x) |
P/CF (x) |
---|---|---|---|---|---|---|
2020A | 6.0 | (47.5) | (46.9) | (205.53) | N/A | N/A |
2021A | 10.2 | (61.9) | (61.5) | (283.46) | N/A | N/A |
2022E | 5.9 | (39.1) | (38.9) | (163.84) | N/A | N/A |
2023E | N/A | N/A | N/A | N/A | N/A | N/A |
Industry outlook
Metastatic cancer is the most advanced stage of cancer and forms the bulk of the current prostate cancer therapy market. RhoVac’s target group is focused on non-metastatic patients with biochemical failure and patients in this group are several times more prevalent than metastatic patients. Preventing or halting metastasis formation in this group of patients by inhibiting the metastatic cascade or killing cells with metastatic potential could reduce morbidity and improve survival.
Last updated on 23/05/2022Content on RhoVac















Sector |
---|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
---|---|
Forecast net debt (SEKm) | 3.6 |
Forecast gearing ratio (%) | 34 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
*% relative to local index |
Key management |
|
---|---|
Anders Månsson | CEO |
You may also be interested in…
- Abliva
- AlzeCure Pharma
- ASIT biotech
- Basilea Pharmaceutica
- BerGenBio
- Cantargia
- Carmat
- Deinove
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- IRLAB Therapeutics
- Kiadis Pharma
- MagForce
- Medigene
- MOLOGEN
- Newron Pharmaceuticals
- Nicox
- Nuevolution
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Pharnext
- Photocure
- Pixium Vision
- Polyphor
- Probiodrug
- Ryvu Therapeutics
- Scandion Oncology
- Sequana Medical
- Targovax
- Transgene
- TxCell
- Ultimovacs
- Vivesto
- Xbrane Biopharma